Showing 1251-1260 of 1414 results for "".
- Nanodropper Completes $1.4 Million Seed Funding Roundhttps://modernod.com/news/nanodropper-completes-1-4-million-seed-funding-round/2479092/Nanodropper, which is making a first-of-its-kind eyedrop bottle adaptor that reduces eyedrop size, recently completed a $1.4 million seed round. Golden Seeds, a recognized leader in the movement to accelerate funding to women en
- CooperVision Introduces 2021 Best Practices Honoreeshttps://modernod.com/news/coopervision-introduces-2021-best-practices-honorees/2478943/During a year of unprecedented challenges brought on by the COVID-19 pandemic, eye care practices across the nation have adapted to meet the changing needs of their patients and find ways to not only survive, but thrive. In celebration of 10 such practices, CooperVision announced its 2021 Bes
- Innovent Announces NMPA Granted New Indication Approvals for Sulinno for the Treatment of Pediatric Plaque Psoriasis and Noninfectious Uveitishttps://modernod.com/news/innovent-announces-nmpa-granted-new-indication-approvals-for-sulinno-for-the-treatment-of-pediatric-plaque-psoriasis-and-noninfectious-uveitis/2478695/Innovent Biologics announced that Sulinno (adalimumab injection), a recombinant human anti-TNF-α monoclonal antibody drug, has been officially approved by the National Medical Products Administration (NMPA) of China for two new indications, including the treatment
- Regeneron’s Inmazeb Becomes First FDA-Approved Treatment for Ebola Virushttps://modernod.com/news/regenerons-inmazeb-becomes-first-fda-approved-treatment-for-ebola-virus/2478420/The FDA announced Wednesday that it has approved Regeneron Pharmaceuticals’ triple antibody cocktail Inmazeb (atoltivimab/maftivimab/odesivimab-ebgn) for use in adult and paediatric patients, making it the first drug cleared in the US to treat Ebola virus infection. According to the a
- Early Data Show Regeneron’s Antibody Cocktail Cuts Viral Load, Eases COVID-19 Symptomshttps://modernod.com/news/early-data-show-regenerons-antibody-cocktail-cuts-viral-load-eases-covid-19-symptoms/2478347/Regeneron Pharmaceuticals said Tuesday that adding REGN-COV2 to standard-of-care reduced viral load as well as the time to symptom alleviation in non-hospitalized patients with COVID-19. The company noted that first data from an ongoing adaptive phase 1/2/3 trial of its investigational dual antib
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- Aviceda Therapeutics Appoints Biopharma and Business Veterans to its Board of Directorshttps://modernod.com/news/aviceda-therapeutics-appoints-biopharma-and-business-veterans-to-its-board-of-directors/2478284/Aviceda Therapeutics has announce the appointment of Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA, to their board of directors, effective immediately. Aviceda is a preclinical stage biotech company focused on the next generation of glyco-immune therapeutics utilizing the Glyco-Code technolog
- Nanodropper Awarded a Phase 2 SBIR Contract With US Air Forcehttps://modernod.com/news/nanodropper-awarded-a-phase-2-sbir-contract-with-us-air-force/2478191/Nanodropper, the maker of an eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a phase 2 Small Business Innovation Research (SBIR) contract with the United States Air Force. The Nanodropper adaptor was inspired by a 2017 ProPublica article detailing just how
- How COVID-19 is Shaking Up Medical Education—For Goodhttps://modernod.com/news/how-covid-19-is-shaking-up-medical-education-for-good/2478168/With COVID-19 shows no signs of letting up soon, leaders at medical schools are adapting their plans for education in the fall to meet the new demands of the pandemic, according to a FierceHealthcare report. That means going digital in an unprecedented way—both in terms of classe
- Ocugen Receives Fourth FDA Orphan Drug Designation for Gene Therapy for the Treatment of Another Inherited Retinal Diseasehttps://modernod.com/news/ocugen-receives-fourth-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-another-inherited-retinal-disease/2478149/Ocugen announced the FDA granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and